EMA Withdrawn: Repso (leflunomide) — Teva B.V.

View source ↗

Summary

The EMA has withdrawn Repso (leflunomide) from the market, a disease-modifying antirheumatic drug previously used for rheumatoid arthritis and psoriatic arthrit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• Repso (leflunomide)

Snippet

Status: Withdrawn. Therapeutic area: Arthritis, Rheumatoid;Arthritis, Psoriatic. MAH: Teva B.V.. Decision date: 30/03/2016